Lucid PSYCH
Alternative Names: Lucid-201; Lucid-PSYCHLatest Information Update: 27 Mar 2023
Price :
$50 *
At a glance
- Originator Lucid Psycheceuticals
- Developer Lucid Psycheceuticals; University Health Network
- Class Antidepressants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Major depressive disorder
Most Recent Events
- 22 Mar 2023 The Alfred Ethics Committee in Australia approves clinical trial application for Lucid PSYCH for phase-I trial in Major depressive disorders
- 31 May 2022 FSD Pharma plans to file an IND application for Major depressive disorders by the end of 2022
- 08 Dec 2021 FSD Pharma plans a phase I trial for Major depressive disorder in the fourth quarter of 2022 (FSD Pharma pipeline, December 2021)